IL17A and pulmonary fibrosis: Consequently, the IL-17A antibody decreased bleomycin-induced pulmonary fibrosis as evidenced by decreased fibrosis-related Szapiel’s score, Ashcroft scores and reduced collagen deposition (Fig. 6A and B).